Stock Research Report for Bajaj Healthcare Ltd
Stock score of Bajaj Healthcare Ltd moved down by 1 in a month on a 10 point scale (Source: Refinitiv). Get detailed report on Bajaj Healthcare Ltd by subscribing to ETPrime.
Get 4000+ Stock Reports worth₹ 1,499* with ETPrimeat no extra cost for you
*As per competitive benchmarking of annual price. T&C apply
Make Investment decisions
with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum
Find new Trading ideas
with weekly updated scores and analysts forecasts on key data points
In-Depth analysis
of company and its peers through independent research, ratings, and market data
Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. It operates through three segments: APIs, Finished Dosage Formulations (FDFs), and Intermediates. Its APIs include Ascorbic Acid IP, Sodium Ascorbate, Ferrous Ascorbate, and others. Its Intermediary products include Calcium Phosphoryl Choline Chloride (CPCC) and Chlorhexidine (CH Base). It offers a range of FDFs forms, including tablets, caplets, capsules, and oral powders, all available in bulk quantities. The FDFs products include Cholecalciferol Sachet, Ticagrelor Tablet, Pancreatin Capsules, levofloxacin Tablets IP, Bisacodyl Tablet IP, and others.
